Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
https://doi.org/10.17650/1818-8346-2009-0-1-14-20
Abstract
The purpose of this study was evalueted of a long-term treatment outcome in chronic myeloid leukemia (CML) patients in accelerated phase treated with GlivecR and determination of an optimum therapy schedule. 105 patients (men — 46, women — 59) at the age from 15 till 74 years (a median age — 40 years) enrolled between 02.2001 and 02.2007 were studied. Treatment started a dose of 600 mg/day. At the insufficient primary therapy response or loss complete hematological and/or complete cytogenetic remission in the course of treatment, dose have been increased to 800 mg/day. In 82 (78.1%) patients complete hematological remissions have been reached. In 44 (41.9%) patients complete cytogenetic response (CR) is received, and in 27 (61.4 %) of them with molecular response: complete — 17 (63%) and major — 10 (27%). 6-year overall survival rate (OS) was 61.9%, 6-year event-free survival rate (EFS) — 30.5%. Achievement of complete CR was a predictor of long longterm survival rate: OS — 95.5% versus 37.7 % (р <0.001). In case of absence CR (n=16) imatinib dose escalation allowed to receive complete CR in 5 (31.25%) and minor — in 4 (25.0%) patients. Loss or absence of complete CR on imatinib therapy not always leads to CML progression: in 18 (17.1 %) patients without complete CR hematological parameters remain normal and there are no signs of disease progression.
About the Authors
L. A. Antipova
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Moscow
S. S. Loria
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Moscow
S. V. Semochkin
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Moscow
A. G. Rumiantsev
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Moscow
References
1. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105(7):2640—53.
2. Druker B., Talpaz M., Debra J. et al. Efficacy and safety of specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031—7.
3. Семочкин С.В., Лория С.С., Курова Е.С. и др. Анализ качества жизни больных хроническим миелолейкозом в фазе акселерации на фоне терапии гливеком. Совр онкол 2002;4(2):67—70.
4. Курова Е.С. Клиническая эффективность молекулярно-направленной терапии в фазе акселерации хронического миелолейкоза. Автореф. дис. …канд. мед. наук. М., 2004.
5. Kantarjian H., Talpaz M., O'Brien S. еt al. Survival benefit with imatinib mesylate therapy in patients with acceleratedphase chronic myelogenous leukemia —comparison with historic experience. Cancer 2005;103(10):2099—108.
6. Piazza R.G., Magistroni V., Franceschino A. et al. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. Blood Cells Mol Dis 2006;37(2):111—5.
7. Guilhot F., Chastang C., Michallet M. et al. Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223—9.
8. Kantarjian H.M., Keating M.J., Estey E.H. et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J Clin Oncol 1992;10:772—8.
9. Baccarani M., Saglio G., Goldman J. et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia net. Blood 2006;108:1809—20.
10. Туркина А.Г., Хорошко Н.Д. Практические рекомендации по лечению больных хроническим миелолейкозом (пособие для врачей). М.: Триада, 2005.
11. NCI: Common Toxicity Criteria manual, version 2.0. Bethesda (MD): National Cancer Institute. 1999. p. 1—35.
12. Druker B.J., Talpaz M., Resta D. et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031—7.
13. Pinkel D., Straume T., Gray J.W. Cytogenetic analysis using quantitative, highsensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 1986;83(9):2934—8.
14. Gabert J., Beillard E., van der Velden V.H. et al. Standartisation and quality control studies of ≪real-time≫ quantitative reverse transcryptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia. A Europe Against Cancer program. Leukemia 2003;17:2318—57.
15. Talpaz M., Silver R.T., Druker B.J. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928—37.
16. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457—61.
17. Cox D.R. Regression models and life tables. J Royal Stat Soc 1972; Series B (34):187—220.
18. Hehlmann R., Heimpel H., Hasford J. et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993;82(2):398—407.
Review
For citations:
Antipova L.A., Loria S.S., Semochkin S.V., Rumiantsev A.G. Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®). Oncohematology. 2009;(1):14-20. (In Russ.) https://doi.org/10.17650/1818-8346-2009-0-1-14-20
Views:
665
Email this article 